CLINICAL_TRIALS
trial_result
· 2020-08-04
Clinical Trial Update: Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) [Phase 3]
Summary
Phase 3 trial of ataluren in nonsense mutation Duchenne muscular dystrophy completed; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: PTC Therapeutics | Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies | Phase 3 | Status: COMPLETED | Results posted: 2020-08-04